Search 

TRACTIVUS is a company derived from the research group GEMAT (IQS-Ramón Llull University) and IDIBELL (Bellvitge Biomedical Research Institute), located in Barcelona. We are an innovative company with expertise in antibacterial coatings, easy to be implemented on a wide range of medical devices.

PHOBOSTech™ technology have been developed over the years in Tractivus SL as a solution to the current problems of medical devices. Our cost-effective patented technology allows to create nanostructures on the surface, preventing bacteria attachment and, therefore, bacteria colonization. As a result our devices show higher lifetime, lower associated costs, and no post-implantation problems without adverse effect on the patients.

Tractivus SL combines the experience of the research groups and a unique solution designed to root out the colonization of the devices through a micro- and nano-structured coating that protects the device from adhesion and bacterial colonization. The team has worked on all aspects of the development: material selection, regulatory strategy, risk reduction, clinical trials, partners, stakeholders... aiming to maximize the success of both the project and the investors.

Trove is a semi-virtual biotech start-up located in Rockville, Maryland, USA, developing an advanced biologic asset and seeking funding and partners to conduct clinical trials in respiratory disease. We have data and drug supply on our lead, clinical-stage biologic asset to support up to 3 clinical trials in different respiratory conditions (2 x Phase 1b/2a in COVID and lung transplant; and 1 x Phase 2 in chronic sinusitis). Our biologic, called Therabron, is a replacement for a normally abundant native protein that is deficient in our targeted indications. Replacement therapies have a high approval rate with FDA (>70%) and patients with genetic deficiencies can be selected in some trials to increase our chances of demonstrating efficacy. Therabron was safe in 3 early studies. At present, the quickest path to an approval is likely an Emergency Use Authorization in severe COVID-19 patients, so we're looking for an initial $2M seed/Series A round to fund a Phase 1b/2a clinical trial then need another $16M to produce more drug and perform a convincing Phase 2 trial. We are already talking to several potential corporate partners, have signed one CDA with a top 5 pharma, and a relatively small amount of investment in clinical proof of concept demonstrations will attract at least one partner. Once clinical POC is established in targeted indications, we plan to exit via sale/acquisition or out-license. Our markets are large (3 products x >$1B each US) and deal comps in the respiratory space are $250M each and up. We can maximize our ROI by out-licensing the first indication and re-investing upfront license payment proceeds to advance the drug in further indications, depending on what happens in each field/indication and what we (management team and investors) decide to do.

Bio-Tech

VISEN Pharmaceuticals, headquartered in Shanghai, China, is committed to the treatment of endocrine-related disease, introducing the world’s leading treatment methods and drugs into the China market, benefiting Chinese patients while unleashing product potential.

VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology rare disease therapies in Greater China. The pipeline of VISEN covers pediatric endocrinology, adult endocrinology, and rare disease. VISEN management team has extensive experience in the development and commercialization of endocrine disease products in Greater China. VISEN has a deep understanding of unmet medical needs in Chinese patients and is actively expanding its pipeline through in-licensing and partnership.

Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).

We have, by a wide margin, the safest and most effective nocturia drug. Nocturia leads to over 10,000 deaths per day and costs the US economy $215B/year in lost worktime and lower productivity.

Whale Bay & Co is a boutique financing firm focused solely on the life sciences industry. Based in Rotterdam (the Netherlands) and Basel (Switzerland) we serve SME's, investors and mid-size strategic companies in Biotech, Pharma, MedTech and Digital Health in the strategy and financial space: licensing, financing, M&A, valuation and outsources BD. We have a keen interest to expand our network and business into China. In the context of specific mandates we would like to connect with:

- pharma & medtech companies for outlicensing/JV collaborations with our clients
- investors looking for early and late stage pharma, biotech and medtech investment opportunities
- (FoF)investors interested in investment in funds

Wuxi High-tech zone is focusing on developing biopharmaceutical industry. It is one of the top high-tech zones in China. There are a number of famous biopharmaceutical companies such as AstraZeneca, Wuxi AppTech.